MTX+ACTD

Small molecule

WWomen's Hospital School Of Medicine Zhejiang University

MTX+ACTD is one of 11 small molecule programs targeting Gestational Trophoblastic Neoplasm. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Gestational Trophoblastic NeoplasmActive, not recruiting

Gestational Trophoblastic NeoplasmPhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

12 competitors in Gestational Trophoblastic Neoplasm

#DrugCompanyPhaseTrials

Trexall

Alnylam Pharmaceuticals

Femara

Cosmegen

Keytruda

Bavencio

Jemperli

GGlaxo Dba Glaxosmithkline

Phase 2

—7

Wellcovorin

EEastern Cooperative Oncology Group

Phase 2

—8

Tuoyi

SSun Yat-sen University

Avastin

Alimta

GGynecologic Oncology Group

Phase 2

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Gestational Trophoblastic Neoplasm1 trial

Combination of Methotrexate(MTX) and Actinomycin(ACTD) in the Low Risk Gestational Trophoblastic Neoplasma （GTN） Patients With Score of 5-6

Unknown status·WWomen's Hospital School Of Medicine Zhejiang University·Phase 2/3·NCT03885388·300 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for MTX+ACTD. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MTX+ACTD compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MTX+ACTD. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Women's Hospital School Of Medicine Zhejiang University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: WWomen's Hospital School Of Medicine Zhejiang University

MTX+ACTD

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Gestational Trophoblastic Neoplasm1 trial

References

Drug Info

Quick Facts

Related News